P. vivax and P. falciparum parasites display different tropism for host cells and induce very different clinical symptoms and pathology, suggesting that the immune responses required for protection may differ between these two species. However, no study has qualitatively compared the immune responses to P. falciparum or P. vivax in humans following primary exposure and infection. Here, we show that the two species differ in terms of the cellular immune responses elicited following primary infection. Specifically, P. vivax induced the expansion of a subset of CD8 + T cells expressing the activation marker CD38, whereas P. 
falciparum induced the expansion of CD38 + CD4 + T cells. The CD38 + CD8 + T cell population that expanded following P. vivax infection displayed greater cytotoxic potential compared to CD38 -CD8 + T cells, and compared to CD38 + CD8 + T cells circulating during P.
falciparum infection. We hypothesize that P. vivax infection leads to a stronger CD38 + CD8 + T cell activation because of its preferred tropism for MHC-I-expressing reticulocytes that, unlike mature red blood cells, can present antigen directly to CD8 + T cells. This study provides the first line of evidence to suggest an effector role for CD8 + T cells in P. vivax bloodstage immunity. It is also the first report of species-specific differences in the subset of T cells that are expanded following primary Plasmodium infection, suggesting that malaria vaccine development may require optimization according to the target parasite.
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Introduction
Malaria vaccine research efforts have been directed predominantly at P. falciparum, since globally it is the major cause of malaria-related mortality [1] . However, it is now recognized that P. vivax is poised to become the dominant species in areas where it is endemic [2] and can be associated with severe pathology [2, 3] . Yet, compared to what is known about responses to P. falciparum, little is known about immune responses to P. vivax infection. This lack in knowledge is due in part to confounders that are present in samples from naturally-infected individuals living in malaria-endemic regions where parasitic co-infections and cross-species immunity are present; and technical difficulties associated with experimental infection of humans due to a lack of a method for the continuous in vitro culture of P. vivax [4] . It has been generally assumed that P. vivax would elicit similar immune responses compared to P. falciparum. However, the two parasites display very different features in terms of life cycle, invasion mechanism and immunopathology [2, 3, 5] and thus may generate distinct host specific immune responses. A few studies have compared global frequencies of circulating lymphocyte populations during P. falciparum or P. vivax infection in naturally infected humans [6, 7] , but have not investigated their activated or effector phenotype. The recent establishment of different models of Controlled Human Malaria Infection (CHMI) provides the opportunity to obtain samples from malaria-naive healthy volunteers following first exposure to Plasmodium blood-stage parasites, thereby greatly enhancing our understanding of the host-parasite immune response [8, 9] . Until recently, such experimental infection studies could be done only with P. falciparum due to the lack of a continuous in vitro culture system of P. vivax as a source of parasitized red blood cells [8] . Recently, however, a cell bank of cryopreserved P. vivax infected erythrocytes was successfully derived from a naturally-infected individual and used to experimentally infect malaria-naive healthy adult volunteers, establishing for the first time a CHMI model with P. vivax [10] .
Here, we have taken advantage of this novel resource to compare cellular immune responses generated following experimental blood-stage infection of naive volunteers with P. vivax or P. falciparum. Overall, we found marked differences in the immune profiles generated following infection with the two species. Specifically, P. vivax but not P. falciparum infection led to the expansion of a specific subset of CD8 + T cells which were associated with an activated phenotype and cytotoxic potential. This study enhances our understanding of P. vivax associated immunity and Plasmodium species-specific immunity, identifying for the first time components of the immune response to blood-stage infection that are species-specific. 
Sample collection and processing
Inoculum preparation, volunteer recruitment, infection, monitoring and treatment were performed as described previously for P. falciparum [11] or P. vivax [10] . In brief, healthy malaria-naive individuals were intravenously inoculated with freshly thawed P. falciparum 3D7 or P. vivax parasitized erythrocytes and treated with anti-malarial drugs when the parasitemia exceeded the approximate threshold of 10,000 parasites/mL, at day 7-8 post-infection or day 14 post-infection for P. falciparum or P. vivax, respectively. 
Determination of parasitemia and kinetics
Parasitemia was determined using a consensus P. falciparum or P. vivax species-specific quantitative PCR assay as previously described [12] . Parasite levels were assessed once daily until day four post-infection and then twice daily until treatment. All samples were batch tested in triplicate together after each study completion. Limit of detection was 64 parasites/ml [12] . Exponential growth equation fitting parasitemia kinetics for P. falciparum or P. vivax infected volunteers was calculated with GraphPad Prism (version 6.0).
Ex vivo phenotyping of lymphocytes by flow cytometry on whole blood CD107a-based degranulation assay 
Results
P. falciparum and P. vivax primary blood-stage infection in humans generated similar parasitemia curves P. falciparum and P. vivax experimental infection of malaria-naive volunteers was performed under similar procedures [10, 11] . However, due to logistical reasons associated with parasite density in the inoculum stock, and a lack of a continuous in vitro culture system for P. vivax [4] , the infecting dose for P. vivax was estimated to be 15-fold lower than that used in the P. falciparum studies (Khoury D & McCarthy JS, in preparation). Demographics of P. falciparum and P. vivax infected volunteers were comparable in term of age, gender, BMI and ethnicity (S1 Table) . Parasitemia growth curves determined by quantitative PCR (qPCR) from P. falciparum and P. vivax experimental infection studies were similar for both parasites (Fig 1 and Table 1 ) except for the delayed onset of detectable blood-stage parasitemia with P. vivax. Specifically, P. falciparum parasites were detected as early as day 4 of infection whereas P. vivax parasites were detected at day 8 of infection, consistent with the differences in the size of the starting inocula. Interestingly, all individuals infected with P. vivax developed symptoms of malaria before the time of treatment while more than 40% of P. falciparum infected individuals were asymptomatic until anti-malarial drug administration (S2 Table) .
P. falciparum and P. vivax primary blood-stage infection in humans elicited qualitatively different immune responses
In order to compare cellular immune responses to infection between P. falciparum and P. vivax infected volunteers, we determined the phenotype of lymphocytes ex vivo from whole blood samples obtained prior to infection and during infection once the parasitemia exceeded 10,000 parasites/mL (which corresponded to day 7 and day 14 for P. falciparum and P. vivax infected volunteers, respectively). CD38 is a surface glycoprotein that modulates cell adhesion, signal transduction and intracellular Ca 2+ levels, and is specifically upregulated on lymphocytes following activation [13] . We have recently shown that the frequency of CD38 + T cells and B cells circulating in the peripheral blood of test volunteers was dynamically regulated during experimental blood-stage infection with P. falciparum and that the expansion of CD38 + CD4 + T cells following infection was inversely correlated with parasite burden [14] . Thus, we compared the frequencies of CD38 + T cells and B cells circulating before and after infection in P. falciparum or P. vivax infected volunteers. There was a higher frequency of CD38 + CD4 + T cells circulating following infection in P. falciparum but not P. vivax infected volunteers (Fig  2A) . Conversely, P. vivax infection but not P. falciparum elicited a higher frequency of Parasite levels in peripheral blood of infected volunteers were determined using consensus Plasmodium species-specific qPCR as previously described [12] . Blood samples used to assess immune responses were collected prior to infection. Graphs show mean data from 19 volunteers from three independent cohorts (P. falciparum) and 8 volunteers from four independent cohorts (P. vivax); error bars indicate SD. (Fig 2B) . No significant differences were observed in the frequency of CD38 + B cells circulating following infection with P. falciparum or P. vivax (Fig 2C) .
There was no correlation between the expansion of CD38 + CD8 + T cells following infection and parasite burden (S1 Fig). Overall, these data suggest that the quality of the immune response generated following primary blood-stage infection in humans is Plasmodium speciesdependent.
CD38 + CD8 + T cells expanded in P. vivax infection are associated with a cytotoxic function
Since very little information on P. vivax protective immune responses is available, we aimed to further understand the contribution of CD38 + CD8 + T cells to P. vivax blood-stage immunity.
Effector CD8 + T cells perform classical cytotoxic functions by killing infected cells through perforin-mediated dependent mechanisms. To determine the cytotoxic potential of CD38 + CD8 + T cells generated during P. vivax infection, we measured their intracellular expression of granzyme B and perforin by flow cytometry, in an independent cohort (n = 2 because of logistics associated with vivax experimental infection). We found similar expression of granzyme B Plasmodium vivax Blood-Stage Infection Is Associated with Cytotoxic CD8 + T Cells and perforin in CD38 + and CD38 -CD8 + T cells before infection (Fig 3A and 3B) . However, post-infection, CD38 + CD8 + T cells had a greater expression of granzyme B and perforin compared to CD38 -CD8 + T cells (Fig 3A and 3B) . Additionally, CD38 + CD8 + T cells circulating during infection contained a higher amount of granzyme B and perforin in P. vivax infected volunteers compared to P. falciparum infected volunteers (Fig 3C and 3D) whereas no differences were observed prior to infection. In order to further investigate the cytotoxic potential of CD38 + CD8 + T cells and CD38 -CD8 + T cells circulating during P. vivax infection, we tested their ability to degranulate in vitro following TCR stimulation. Prior to infection, CD38 + and CD38 -CD8 + T cells had the same ability to degranulate, whereas post-infection CD38 + CD8 + T cells had a higher degranulation compared to CD38 -CD8 + T cells (Fig 4) .
Overall, these findings suggest that CD38 + CD8 + T cells have a greater cytotoxic potential compared to CD38 -CD8 + T cells and that this cytotoxic function is specifically activated in the CD38 + CD8 + T cells circulating during P. vivax infection but not P. falciparum infection.
Discussion
Herein we report on the first study to compare the quality of cellular immune responses elicited in humans by experimental blood-stage infection with P. vivax or P. falciparum. In this study we utilized a model of controlled infection of malaria-naive human volunteers, thereby avoiding potential confounders of pre-existing immunity and cross-species immunity. We found marked differences between responses to the two Plasmodium species in terms of the phenotype of T cells that expanded during infection. P. falciparum infection elicited a significant expansion of CD38 + CD4 + T cells whereas P. vivax infection led to the expansion of CD38 + CD8 + T cells. We have recently shown that the frequency of circulating CD38 + CD4 + T cells was significantly increased following experimental infection with P. falciparum and inversely correlated with parasite levels [14] . Here we show that P. vivax blood-stage infection elicited a substantially different type of immune response compared to P. falciparum, with significant changes in the CD8 + T cell compartment rather than in the CD4 + T cell compartment.
There was no significant association between the expansion of CD38 + CD8 + T cells and parasite burden in P. vivax infected volunteers, suggesting that the expansion of CD38 + CD4 + T cells in P. falciparum infection and the expansion of CD38 + CD8 + T cells in P. vivax infection might have distinct contributions to the immune response to blood-stage infection. A possible explanation for the qualitative differences observed between P. falciparum and P. vivax associated immune responses may relate to their distinct tropism during blood-stage infection. P. vivax merozoites preferentially invade reticulocytes [15] which, although they are enucleated, still express MHC-I molecules which remain from the nucleated reticuloblast stage. This is in contrast to mature erythrocytes that have completely lost expression of MHC molecules. Previous work using a genetically engineered mouse model of murine malaria has shown that CD8 + T cells can be activated by parasitized erythroblasts but not parasitized mature red blood cells through MHC-I dependent mechanisms [16] . Thus, we hypothesize that the higher proportion of infected reticulocytes in P. vivax infection leads to the activation of a higher proportion of CD38 + CD8 + T cells in an MHC-I dependent manner in comparison to P. falciparum infection.
While it is established that CD4 + T cells and parasite-specific antibodies are critical for protective immune responses to blood-stage malaria [17] , the contribution of CD8 + T cells is less clear. Studies in mice have shown that CD8 + T cells were activated and associated with protective function in lethal [18] or chronic [19] blood-stage malaria. However, no association between CD8 + T cells and protective immunity to primary blood-stage infection in humans Hence their function might be to kill parasitized reticulocytes through MHC-I dependent and perforin-mediated mechanisms. This proposal is further supported by the enhanced expression of cytotoxic molecules observed in CD38 + CD8 + T cells circulating during P. vivax compared to P. falciparum infection. In contrast, we could not identify an expansion of cytotoxic CD8 + T cell population following P. falciparum infection of malaria-naïve volunteers.
These findings have important implications in regard to P. vivax vaccine development. Indeed, most efforts so far have been directed toward the direct translation of the findings associated with P. falciparum vaccine development to P. vivax [20] (e.g. the use of ortholog antigens that were shown to be protective against P. falciparum). Here we show that P. falciparum and P. vivax elicit qualitatively different immune responses and are likely to require distinct vaccine-induced immune responses for protection. Thus, the immunization strategy may need to be adapted for each Plasmodium species to mount optimal protective immune responses, and the design of a universal vaccine conferring protection against multiple Plasmodium species might be conceptually more challenging than initially thought.
In conclusion, in this study we report that primary exposure of humans to different Plasmodium species elicited qualitatively distinct immune responses: P. falciparum infection generated changes in CD4 + T cells whereas P. vivax preferentially activated a subset of CD8 + T cells expressing the activation marker CD38 and associated with a cytotoxic function. 
